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Background: Glycosylation is one of the most fundamental post-translational
modifications. Importantly, glycosylation is altered in many cancers. These alterations
have been proven to impact on tumor progression and to promote tumor cell survival.
From the literature, it is known that there is a clear link between chemoresistance and
hypoxia, hypoxia and epigenetics and more recently glycosylation and epigenetics.
Methods and Results: Our objective was to investigate these differential parameters,
in an in vitro model of ovarian and breast cancer. Ovarian (A2780, A2780cis, PEO1,
PEO4) and triple negative breast cancer (TNBC) (MDA-MB-231 and MDA-MB-436) cells
were exposed to differential hypoxic conditions (0.5–2% O2) and compared to normoxia
(21% O2). Results demonstrated that in hypoxic conditions some significant changes
in glycosylation on the secreted N-glycans from the ovarian and breast cancer cell
lines were observed. These included, alterations in oligomannosylated, bisected glycans,
glycans with polylactosamine extensions, in branching, galactosylation and sialylation in
all cell lines except for PEO1. In general, hypoxia exposed ovarian and TNBC cells also
displayed increased epithelial to mesenchymal transition (EMT) and migration, with a
greater effect seen in the 0.5% hypoxia exposed samples compared to 1 and 2% hypoxia
(p ≤ 0.05). SiRNA transient knock down of GATA2/3 transcription factors resulted in a
decrease in the expression of glycosyltransferases ST3GAL4 and MGAT5, which are
responsible for sialylation and branching, respectively.
Conclusions: These glycan changes are known to be integral to cancer cell survival
and metastases, suggesting a possible mechanism of action, linking GATA2 and 3, and
invasiveness of both ovarian and TNBC cells in vitro.
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INTRODUCTION
Ovarian cancer and breast cancer, although organ specific
neoplasms, have genomic and biological similarities. For
example, (i) ∼5% of breast cancers [mostly triple negative breast
cancers (TNBCs) (1)], and 10% of ovarian cancers (2), carry a
BRCA1/2 mutation, (ii) both are associated with high relapse
rates and high proportions of chemo-resistance and (iii), both
display an innately hypoxic tumor microenvironment which
has been shown to up regulate a “stem cell-like” property; a
property integral to the progression of these tumors (3–5). As
the tumor grows in size, so does its energy demand and its need
for oxygen. When the oxygen demand outweighs the availability
of oxygen in the tumor it becomes hypoxic. The association
between hypoxia and chemo-resistance has been widely reported
(5). In addition, Watson et al. (6) have demonstrated epigenetic
signatures which promoted and maintained a hypoxic-adapted
cellular phenotype in benign prostate epithelial cells, with a
potential role in prostate cancer development (6). Shahrzad et al.
(7) published that the hypoxic conditions observed in tumors
resulted in the global DNA hypomethylation we traditionally
associate with cancer (7). Methionine adenosyltransferase (MAT)
is encoded by two genes in mammals, namely MAT1A and
MAT2A, and catalyzes the production of S-adenosyl methionine
(SAM) (8). SAM is a methyl donor substrate, used in many
cellular processes, including DNA and histone methylation (9).
Liu et al. (9) have shown that MAT2A has a hypoxia responsive
element (HRE) motif within its promoter region, where HIF-1α
binds, resulting in the up regulation ofMAT2A gene transcription
in hypoxia (1%) (9). GATA3, a transcription factor (TF) involved
in the development of numerous biological responses and specific
tissue development, has also been shown to interact with, and
stabilize HIF-1α (10). It has also been demonstrated that the
GATA TF family are heavily dependent on CpG island promoter
methylation for activation/repression (11). Interestingly, GATA3
a gene, which has a role in Th2-cell differentiation, shows
differential methylation status on Th1 cells compared toTh2
cells (12).
The potential link between hypoxia and glycosylation is
less well-understood. MiR-200b, known to be downregulated
in hypoxia (1%), is associated with fucosylation (13, 14).
Shirato et al. (15) have also shown that 1% hypoxia alters
glucose metabolic fluxes, that can modulate cellular glycosylation
patterns (15). In addition, Ren et al. (16) have demonstrated
that certain N-linked glycosylation sites on integrin-α3 are
important for cell to cell adhesion, and that modification to
these glycans results in a potential EMT phenotype (16). DNA
methylation and glycosylation have been shown to be involved
in the regulation of EMT, apoptosis, senescence, and autophagy
(17–24). It is therefore likely, that the tumor microenvironment
of hypoxia will affect these processes. It is also accepted that
activation of HIF signaling, influences numerous steps in the
metastatic cascade, including invasion, migration, extravasation
and intravasation (25).
In this study, our objective was to demonstrate the impact of
hypoxia on glycosylation profiles from the secreted glycoproteins
of ovarian and breast cancer cells in-vitro, and determine




A2780, PEO1, PEO4, MDA-MB-231, MDA-MB-436 were
authenticated in 2015/16 by DDC medical, via short tandem
repeat (STR) profiling. A2780cis cells were obtained from
The European Collection of Authenticated Cell Cultures
(ECACC). All cell lines were maintained in RPMI 1640 medium
supplemented with 10% v/v fetal calf serum (FCS) and 2mM
L-glutamine. PEO1 and PEO4 were further supplemented with
1mM sodium pyruvate. All cells were cultured at 37◦C with 5%
CO2. A2780cis cells were treated with 1µM cisplatin every 2/3
passages, to ensure chemo-resistance was maintained. All cell
lines were also routinely tested for Mycoplasma contamination
in the UCD Conway Institute of Biomolecular and Biomedical
Research UCD, Dublin.
Incubation of Cells in Hypoxic (0.5, 1, and
2%) Conditions
To ensure a sustainable deficiency of oxygen, cells were incubated
in a hypoxic chamber under 0.5, 1, and 2% O2 for a 24 and
48 h period, respectively, with media preconditioned to the
relative oxygen environment for at least 12 h prior to culturing.
The 48 h hypoxia exposed cell line media was replenished with
preconditioned media after 24 h. Following incubation, the cells
were immediately harvested and depending on the analysis being
performed, cell pellets were fixed in 70% methanol, or frozen at
−20◦C, for up to 6 weeks or−80◦C for longer periods for western
blot and subsequent TaqMan R© RT-qPCR analyses.
Flow Cytometry
Cells were harvested by trypsinisation, fixed in 70%methanol and
subsequently stained with Propidium Iodide (PI) (Sigma) and an
anti-5′methylCytidine (5′MeC) (Eurogentec) primary antibody.
Prior to staining with 5′MeC, the cells were pre-incubated with
1M HCl at 37◦C for 1 h. IgG negative controls were used at the
same concentration as the primary antibody. Secondary antibody
staining was conducted using an FITC conjugated rabbit anti-
mouse secondary antibody (Dako). Analyses were performed on
an Accuri C6 flow cytometer and results assessed using FCS
Express software (De Novo).
Cell Secretome Harvesting
Supernatants were spun down and concentrated using Amicon
Ultra-15 10K ultrafiltration (Millipore), to a final volume of
below 200 µL. Proteins were precipitated with a half volume of
50:50 TCA: acetone (w/v) on ice. Themixture was then incubated
for 45min on ice and centrifuged at 13,000 rpm for 5min. The
resultant pellet was washed with cold acetone and centrifuged
again at 13,000 rpm for 5min. This final pellet was dried and
resuspended in sample buffer (2% SDS, 62.5mM TRIS pH 6.6)
for subsequent N-glycan analysis.
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Glycan Analysis
N-glycans were released from glycoproteins in samples, by in situ
digestion with Peptide N-glycosidase F (PNGase F; Prozyme) in-
gel blocks (26). Briefly, samples from cell secreted glycoproteins,
were reduced and alkylated, and subsequently set into SDS-
gel blocks. N-glycans were released by adding 50 µL of 1
U/400 µL PNGase F in 20mM NaHCO3, pH 7.2. The reduced
terminus of the oligosaccharides were then fluorescently labeled
with 2-aminobenzamide (2AB) by reductive amination (27). The




HILIC-UPLC was carried out on a BEH Glycan 1.7µM 2.1
×150mm column (Waters), on an Acquity UPLC H-Class
(Waters), coupled with an Acquity fluorescence detector. Solvent
A was 50mM formic acid adjusted to pH 4.4 with ammonia
solution. Solvent B was acetonitrile. The column temperature was
set to 40◦C. The following conditions were used; 30min method
using a linear gradient of 30–47% A at 0.56 mL/min in 23min
(28). Samples of 10µL volumes, were injected in 70% acetonitrile.
Fluorescence was measured at 420 nm, with excitation at 330 nm.
The systemwas calibrated using a 2AB-labeled glucose oligomers,
to create a dextran ladder with retention times of all identified




Lyophilised cell line secretome samples, were reconstituted
in 3 µl of water and 9 µl acetonitrile. Online coupled
fluorescence (FLR)-mass spectrometry detection was performed
using a Waters Xevo G2 QTof with Acquity R© UPLC (Waters
Corporation, Milford, MA, USA) and BEH Glycan column
(1.0 × 150mm, 1.7µm particle size). For MS acquisition data,
the instrument was operated in negative-sensitivity mode with
a capillary voltage of 1.80 kV. The ion source block and
nitrogen desolvation gas temperatures were set at 120 and 400◦C,
respectively. The desolvation gas was set to a flow rate of
600 L/h. The cone voltage was maintained at 50V. Fullscan
data for glycans were acquired over m/z range of 450–2,500.
Data collection and processing were controlled by MassLynx
4.1 software (Waters Corporation, Milford, MA, USA). The
fluorescence detector settings were as follows ex = 330 nm, em
= 420 nm. Sample injection volume was 8 µL. The flow rate was
0.150 mL/min and column temperature was maintained at 60◦C;
solvent A was 50mM ammonium formate in water (pH 4.4) and
solvent B was acetonitrile. A 40min linear gradient was used, and
was as follows: 28% (v/v) A for 1min, 28–43% (v/v) A for 30min,
43–70% (v/v) A for 1min, 70% (v/v) A for 3min, 70–28% (v/v)
solvent A for 1min and finally 28% (v/v) A for 4 min.
Exoglycosidase Digestions
The 2AB-labeled oligosaccharides were digested in a volume
of 10 µL for 18 h at 37◦C in 50mM sodium acetate buffer,
pH 5.5 (with the exception of jack bean α-mannosidase (JBM),
where the buffer was 100mM sodium acetate, 2mM Zn2+,
pH 5.0), using arrays of the following enzymes: Arthrobacter
ureafaciens sialidase (ABS), 0.5 U/mL; Streptococcus pneumoniae
sialidase (NAN1), 1 U/mL; bovine testes β-galactosidase (BTG),
1 U/mL; Streptococcus pneumoniae β-galactosidase (SPG), 0.4
U/mL; bovine kidney α-fucosidase (BKF), 1 U/mL; β-N-
acetylglucosaminidase cloned from Streptococcus pneumonia,
expressed in E. coli (GUH), 8 U/mL (Prozyme) or 400 U/mL
(NEB); jack bean α-mannosidase (JBM), 60 U/mL; almond meal
α-fucosidase (AMF), 0.4 mU/mL. All enzymes were purchased
from Prozyme and GUH, was also purchased from NEB.
Following digestion, the enzymes were removed by filtration
through a Pall 10 kDa MWCO microcentrifuge filtration device
(Pall cat no. 516-8491), and the oligosaccharides were analyzed
by HILIC-UPLC.
Feature Analysis
Glycan peaks were pooled based on similar structural or
compositional features of the peak glycan members. Features
pertaining to a peak were determined based on the major glycan
members of that peak. (See Table S1).
Electrophoresis and Western Blot Analysis
Whole cell extracts were separated by SDS-PAGE using 4–
15% precast TGX gels (BioRad), and transferred onto PVDF
membranes using the Trans-Blot R© TurboTM system (Biorad).
Blots were blocked and incubated with rabbit monoclonal
antibodies targeting PARP (1:1000, Cell Signaling Technologies),
p21 (1:1000, Abcam), p16 (1:1000, Abcam),N-Cadherin (1:1000,
Abcam), GATA2 and GATA3 (Sigma, 1:1000); rabbit polyclonal
antibody targeting LC3 (1:1000, Abcam); and mouse monoclonal
antibodies targeting E-Cadherin (1:500, Abcam), Rb (1:1000,
Abcam), ST3GAL4 (Abcam, 1:500) andMGAT5 (Abcam, 1:400).
The membranes were then incubated with a secondary goat anti-
mouse or anti-rabbit antibody (1:5000, Abcam). The blots were
developed using TMB for enzymatic colourimetric detection.
To analyse protein loading, the mouse monoclonal, α-Tubulin
antibody (1:10,000; Santa Cruz, CA, USA) was used. Western
blots were quantified using ImageJTM software (FIJI).
RT-qPCR (Reverse Transcription
Quantitative PCR)
Eight gene transcripts were analyzed comprising of (i)
glycosyltransferases mannosyl-(α1,6-)-glycoprotein β1,6-N-
acetyl-glucosaminyltransferase (MGAT5) and β-galactoside
α2,3-sialyltransferase 4 (ST3GAL4), (ii) enzymes in the sugar
nucleotide donor pathway GDP-mannose-4,6-dehydratase
(GMDS), mannose phosphate isomerase (MPI) and tissue
specific transplantation antigen P35B (TSTA3) and (iii) TFs,
GATA1, GATA2 and GATA3 identified in a preliminary in-silico
study (Dr. Stephen Madden, DCU). Firstly, total RNA was
isolated from the cells using an RNeasy Mini kit (Qiagen, Cat No.
74104). The RNA (500 ng) was subsequently reverse transcribed
using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). RT-qPCR was then performed using the
following TaqMan assay probes ST3GAL4: Hs00920871 m1,
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MGAT5: Hs00159136 m1, TSTA3: Hs00163023 m1, GMDS:
Hs00155276 m1, MPI: Hs00159228 m1, GATA1: Hs01085823
m1, GATA2:Hs00231119 m1, GATA3:Hs00231122 m1 (Thermo
Fisher), on a 7500 Fast Real-Time PCR System (Applied
Biosystems) to analyse the expression of each RNA by the
comparative delta Ct method, normalized using the TATA box
binding protein (TBP): Hs99999910 m1. TATA is a constitutive
gene and does not vary in the treatments (30–32). Three technical
replicates were performed for each sample and each gene and
PCR assays were carried out in duplicate. Results were expressed
as mean± SD values.
Migration Assay
The OrisTM Cell Migration Assay (Platypus Technologies) was
used to assess cell migration in all cell lines under normoxia
and hypoxia conditions. Conditions were optimized based on
the manufacturer’s instructions. Briefly, 2.5 × 104-5 × 104
cells/well/100 µL were added into stopper-loaded wells and
incubated overnight to permit cell attachment. The stoppers were
removed from the wells to allow cell migration and the wells were
gently washed with PBS. Complete cell culture medium was then
added and the cells/wells incubated for 48 h. Each well was then
washed with sterile PBS to remove any dead cells. The remaining
cells were then fixed using 70% methanol diluted in water and
incubated in Coomassie Instant Blue for 20min. A reading of
each well was taken on a microplate reader (Perkin Elmer) at
595 nm. As a negative control, a set of stoppers were left in place
until the experiment was completed, so the cells were contained
within the stoppers and no migration occurred in this sample.
Transient GATA Knockdown
Cells were transiently transfected with 100 nM of either
siRNA targeting GATA2 (A2780, A2780cis) or GATA3 (PEO1,
PEO4) (Dharmacon) transcripts, and 25nM of scrambled
control siRNA using DharmaFECT1 (Dharmacon) transfection
reagent. DharmaFECT1 volumes and siRNA concentrations were
optimized for a 12 well-plate according to the manufacturer’s
protocol (Figure S1). Briefly, cells were seeded at an optimal
density, so that at the time of transfection the cells were 60–70%
confluent. For A2780 and A2780cis this was 4 × 105 cells/well
the day before transfection and for PEO1 and PEO4 cells this
was 6 × 105 cells/well. On the day of transfection, separate tubes
were prepared with the appropriate volume of DharmaFECT1
(2 µL/well), scrambled siRNA (25 nM final concentration) and
targeted siRNA (100 nM final concentration), diluted in serum
free RPMI media. The DharmaFECT1 was then mixed with the
siRNA and allowed to stand at room temperature for 20min.
At the same time, the media was removed from the 12 well-
plates, and replaced with 800 µL/well of fresh complete growth
media. 200 µL of DharmaFECT1/siRNA mix was then added to
the appropriate wells. The cells were incubated at 37◦C for 24
and 48 h.
Statistical Analysis
All data are expressed as the means ± the standard deviation
(SD). Statistical analyses were performed using SPSS
statistical software for Windows (version 24.0; SPSS Inc.).
For significances in glycan data, individual glycan peaks
and features, the HILIC-UPLC data were logit transformed,
and examined using a MANOVA with post-hoc analysis
using Tukey’s Honest Significant difference. For other data,
such as the RT-qPCR, Western blot densitometry and
migration assays, t-tests, one- or two-way ANOVAs were
used as was deemed appropriate. A p < 0.05 was considered
statistically significant.
Heatmap Histograms
Histograms indicating fold changes in hypoxia conditions
in comparison to normoxia in Figures were created using
Hierarchial Clustering Explorer HCE 3.5 software.
RESULTS
Hypoxia (0.5–2% O2) Alters the Global
Methylation of Breast and Ovarian Cancer
Cell Lines in-vitro
Four ovarian cancer (A2780, A2780cis, PEO1, and PEO4) and
two TNBC (MDA-MB-231 and MDA-MB-436) cell lines were
selected for this study. A2780/A2780cis and PEO1/PEO4 are
pairs of chemosensitive/chemoresistant ovarian cancer cell lines
and were selected to determine if our observed results differ
between chemosensitive/chemoresistant cancer cell lines. The
inclusion of two TNBC cell lines, allowed for comparison with
another tumor type, which like ovarian cancer, is very prone to a
hypoxic tumor microenvironment in-vivo. All cells were cultured
in 0.5, 1, and 2% O2 percentages and compared to normoxic
conditions (21% O2) for 24 and 48 h, to determine the impact
if any that hypoxia had on global cellular DNA methylation.
Hypoxic exposure (0.5 and 1%O2 levels), significantly altered the
global DNAmethylation profile compared with the cells cultured
under normoxic conditions (21% O2) (p ≤ 0.05). There was a
significant increase in DNA methylation (p ≤ 0.05) (up to 60%)
after 24 h and significant decrease in DNAmethylation (p≤ 0.05)
(up to 60%) after 48 h incubation under these hypoxic conditions
for all cell lines (Figure 1).
N-Glycosylation Is Dysregulated in Hypoxia
Exposed Cells
All differential hypoxia cultures (0.5–2% O2) and normoxia
controls (21% O2), at the 24and 48 h timepoint, were analyzed
for detailed N-glycan composition from secreted glycoproteins.
Profiles from each cell type are represented in Figure 2A.
Structural assignments were made using the Glycostore database
(https://glycostore.org/) (33), exoglycosidase digestion arrays as
well as mass spectrometry (MS). The main glycans are presented
in Figure 2B and detailed assignments using UPLC and MS
presented in Tables S2, S3, respectively. Table S1 outlines all
glycans in all cell lines and how the individual glycan peaks
were pooled into the common features. Table 1 summarizes the
glycomic changes in all cell lines. Figure 2C shows colored fold
changes in the percentage areas in the individual peaks from all
samples in hypoxia conditions compared to normoxia controls,
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increases are in red and decreases in blue color. Those stared,
represent significant changes (p ≤ 0.05).
In general, peaks were identified as being significantly
increased or decreased (p ≤ 0.05), 0.08–62.02-fold, in all
cell lines. To see the specific type of glycans affected, the
glycans were pooled into common features (Figure 2D).
Significant alterations are in oligomannosylated, bisected
glycans, glycans with polylactosamine extensions, in branching,
galactosylation and sialylation (p ≤ 0.05) (Figure 2D,
Table 1). Generally, there is a trend for a decrease in
FIGURE 1 | Hypoxia alters global DNA methylation. The histogram represents the average global DNA methylation variation compared to a normoxic control for the 6
cell lines analyzed. Each cell line was exposed to 0.5, 1.0, and 2.0% for 24 h (blue) and 48 h (red). The error bars were calculated from the SD of 3 biological replicates.
Significant changes are starred: * P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 (one-way ANOVA).
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Peak Major glycans Peak Major glycans 
GP1 FA1G1/FA2 GP20 FA2G2S2 
GP2 M5/FA2[6]G1 GP21 A3G3S2 
GP3 FA2[3]G1/A1G1S1 GP22 
A2G2S2/FA2G2S2/ 
A2BG2S2/A3F2G3 
GP4 A2F1G1 GP23 A2BG2S2/FA2G2S2 
GP5 A2F1G1 GP24 A3G3S2 
GP6 A2F1G1 GP25 A3G3S2/FA3BG3S1 
GP7 A2F1G1 GP26 A3G3S3 
GP8 M6 GP27 A3G3S2 
GP9 FA2BG1/FA3G1 GP28 A3G3S3 
GP10 M5A1G1/FA2G2 GP29 A3F1G3(KDN)3 
GP11 FA2BG2/FA3G2 GP30 A3G3S3 
GP12 M7/M4A1G1S1 GP31 A3G3S3 
GP13 A2G2S1 GP32 A3G3S3 
GP14 A2G2S1/A3G3 GP33 A3G3S3 
GP15 M8/FA2G2S1/FA2F1G2 GP34 A3G3S4/M5A2G2S2 
GP16 M8/FA2F2G2 GP35 
FA3BG3S4/ 
FA4F1G1S2 
GP17 M5A2BF1G2Lac1S(6)1 GP36 A2G3Lac1S2 
GP18 A2G2S2 GP37 FA3'BG3S4 
GP19 A2G2S2 GP38 FA4G3S4 
  
A B
FIGURE 2 | continued
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FIGURE 2 | Glycosylation in hypoxia. (A) Typical UPLC chromatograms of secreted N-glycome separated into 38 peaks from ovarian chemosensitive (in blue),
chemoresistant (in orange) and triple negative breast cancer (TNBC) (in red) cells. Highly branched and sialylated glycans are highlighted in green. (B) Main glycans in
each peak. Structure abbreviations: All N-glycans have two core GlcNAcs; F at the start of the abbreviation indicates a core-fucose α1,6-linked to the inner GlcNAc;
Mx, number of mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, biantennary with both GlcNAcs as β1,2-linked; A3, triantennary
with a GlcNAc linked β1,2 to both mannose and the third GlcNAc linked β1,4 to the α1,3 linked mannose; A3’, isomer with the third GlcNAc linked β1-6 to the α1-6
(Continued)
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FIGURE 2 | linked mannose; B, bisecting GlcNAc linked β1,4 to β1,3 mannose; Gx, number of β1,4 linked galactose on antenna; Fx, number of fucose linked α1,3 to
antenna GlcNAc; Sx, number of sialic acids linked to galactose; (C) Plotted peak areas of the N-glycans from secreted glycoproteins from ovarian and breast cancer
cell lines. (D) Plotted features calculated from the peak areas of the N-glycans from secreted glycoproteins from ovarian and breast cancer cell lines [fold difference
between hypoxia conditions and control normoxia (21% O2 )]. Significant changes are starred: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 (MANOVA). The histograms on the
right side of the (C,D) are indicating increasing (in red) and decreasing (in blue) trends in GPs in hypoxia conditions comparing to normoxia.
TABLE 1 | Summary of glycomic changes in all cell lines.
Significantly altered
glycans in hypoxia




























Increased glycans are in red and decreased in green.
Any changes seen in hypoxia are summarized and highlighted (from 0.5 to 2%).
Structure abbreviations: All N-glycans have two core GlcNAcs; F at the start of the
abbreviation indicates a core-fucose α1,6-linked to the inner GlcNAc; Mx, number (x) of
mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; A2,
biantennary with both GlcNAcs as β1,2-linked; A3, triantennary with a GlcNAc linked
β1,2 to both mannose and the third GlcNAc linked β1,4 to the α1,3 linked mannose;
A4, GlcNAcs linked as A3 with additional GlcNAc β1,6 linked to α1,6 mannose; B,
bisecting GlcNAc linked β1,4 to β1,3 mannose; Gx, number (x) of β1,4 linked galactose
on antenna; F(x), number (x) of fucose linked α1,3 to antenna GlcNAc; Sx, number (x) of
sialic acids linked to galactose. Where not specified, the glycan contains sialic acid linked
α2,3 and α2,6.
core fucosylated and oligomannosylated glycans, and an
increase in outer arm fucosylation, polylactosamine extensions
and sialylation on all cell lines (changes range from 0.12
to 4.95-fold) (Figure 2). The most significant of these
glycosylation changes described, were identified on A2780
and A2780cis cell lines (p ≤ 0.05). The results for PEO1 were
different from all other cell lines, but were not statistically
significant (Figure 2).
The presence of ketodeoxynonulosonic acid (KDN, a form of
sialic acid), on triantennary glycans, containing core and outer
arm fucose, was found (3.8–9% of the total glycans, present as a
major glycan in GP29 in all cell lines) (Table S2). This peak was
significantly increased in PEO4 at 1% hypoxia for 24 h (p≤ 0.05)
(Figure 2C).
After the effect of hypoxia on DNA methylation and
glycosylation of secreted glycoproteins was evaluated, additional
cancer cell hallmarks were examined in relation to potential
metastatic capability under hypoxic conditions, which could be
related to the observed glycomics changes. These features were
the epithelial to mesenchymal transition (EMT) and cellular
migration. Cellular apoptosis, senescence and autophagy were
also examined.
Hypoxia Increases EMT and Migration in
All Cancer Cell Lines in vitro
Following determination of the glycosylation changes with
exposure to hypoxia (0.5–2% O2) compared to normoxia
cultured cells, migration and EMT were assessed to determine if
there was a link between altered glycan structures and changes
in migratory capability. Firstly, markers related to EMT were
analyzed in all cell lines. Specifically, E-cadherin, which is
downregulated in EMT and N-cadherin and vimentin, both
known to be upregulated in EMT (34) (Figure 3A, Figure S2).
EMT was significantly increased in A2780 and A2780cis cell lines
(p ≤ 0.05) (up to 30.27 times), with an increased trend observed
in all other cell lines with the exception of PEO4. Specifically for
PEO4, E-cadherin expression was seen to increase (∗), indicating
a decrease in EMT. The two TNBC cell lines MDA-MB-231 and
MDA-MB-436, demonstrated variability in E-cadherin protein
expression following hypoxia exposure. E-cadherin protein
expression was not detectable in A2780, A2780cis, MDA-MB-
231 and MDA-MB-436. N-cadherin expression was not detected
in PEO1, PEO4 and MDA-MB-231. Vimentin was not detected
in PEO4.
The OrisTM Cell Migration Assay was used to assess changes in
migration potential (Figure 3B) following 48 h exposure to 0.5%
hypoxia. Results show that 0.5% hypoxic exposure significantly
increased migration in all cells (p ≤ 0.05) except for MDA-MB-
436. A 1% hypoxia exposure for 48 h, also increased migration
in A2780 and MDA-MB-231 (p ≤ 0.005) and 2% for 48 h in
MDA-MB-231 cells (p ≤ 0.05).
Looking at both the EMT andmigration in hypoxia conditions
(0.5–2% O2), the ovarian PEO1 and TNBC MDA-MB-436 cell
lines were the least affected by hypoxia (Figures 2C,D).
Overall, the increased time of exposure (48 h) and lower O2
percentages applied (0.5%) resulted in more significant increases
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FIGURE 3 | Hypoxic exposure increases migration of breast and ovarian cancer cells; association with markers of EMT. (A) Fold change of the protein expression of
E-cadherin, vimentin and N-cadherin as determined by densitometry (Image J)(Western blots are shown in Figure S3). Each condition was carried out on three
biological replicates (n = 3). (B) Quantification of absorbance readings from the Oris migration assay following hypoxic exposure. Cells were stained with Coomassie
Instant Blue and the absorbance was read at 595 nm. Error bars were calculated from 3 to 6 independent experiments with 4 technical replicates per experiment.
Significant changes are starred: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 (T-test and ANOVA). The histograms on the right side of the figure are indicating increasing (in
red) and decreasing (in blue) trends in EMT markers in hypoxia conditions comparing to normoxia.
observed in their EMT and migration potential (p ≤ 0.05)
(Figures 2C,D).
Senescence and Autophagy Are
Specifically Altered in Hypoxia, Apoptosis
Increases Only in Chemosensitive Cells
Hypoxia induction was confirmed by the increased protein
expression of HIF1α in all conditions, significantly in A2780,
PEO4, MDA-MB-231 and MDA-MB-436 cell lines (p ≤ 0.05, up
to 11.94 times) (Figure 4). There were no significant cell cycle
alterations in hypoxia (Figure S3).
PARP cleavage was significantly increased only in A2780 in
hypoxia conditions (0.5–2% O2, p ≤ 0.05, up to 2.66 times)
compared to A2780 cis. Although not significant, PARP cleavage
increased in the chemosensitive PEO1 and decreased in the
chemoresistant (PEO4) ovarian cells. For the 2 TNBC cell lines,
although not reaching significance, there was increased PARP
cleavage in MDA-MB-231 with increasing hypoxia, with no
PARP cleavage evident in the MDA-MB-436 cells, these changes
were from 0.43 up to 2.66 times (Figure 4).
The senescence marker p21 was significantly decreased in all
hypoxic exposure in PEO4 cells with a concomitant increase in
the autophagy marker LC3. The senescence markers p16, Rb, and
p21 were variably expressed in the cell lines in hypoxia (0.5–2%
O2) (Figure 4). For the TNBC cell lines, there was a significant
increase in P16 for the MDA-MB-231, p ≤ 0.05. However, p16
in hypoxia was not expressed in A2780, A2780cis and PEO4.
P21 decreased in PEO4 and MDA-MB-231 (p ≤ 0.05), and it
was not expressed in MDA-MB-436. The autophagy marker LC3
increased in all cell lines (significantly in A2780cis, PEO1 and
PEO4, p ≤ 0.05). However, the TNBC cell line MDA- MDA-MB-
231, did not express LC3 under these conditions.
Hypoxia Alters the Expression Levels of
MGAT5 and ST3GAL4 Glycosyltransferase
Genes Which Correlate With the
Expression of Transcription Factors (TFs)
GATA2 and GATA3 in Ovarian Cancer Cell
Lines
Glycosyltransferases expression in all cell lines was in general
dysregulated in all hypoxia conditions (Figure 5). Overlaying
multiple regulatory tracks with the human genome (using the
UCSC genome browser, http://genome-euro.ucsc.edu/), we were
able to identify transcription factors (GATA2 and GATA3)
that potentially regulate MGAT5 and ST3GAL4 in our ovarian
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FIGURE 4 | Hypoxia alters apoptosis, senescence and autophagy specifically. Protein expression of HIF1α, PARP, p16, p21, Rb, and LC3 as determined by
densitometry (Image J)(Western blots are shown in Figure S4). Each condition was carried out on three biological replicates (n = 3). Significant changes are starred:
*P ≤ 0.05; **P ≤ 0.01 (T-test). The histograms on the right side of the figure are indicating increasing (in red) and decreasing (in blue) trends in hypoxia, apoptosis,
senescence and autophagy markers in hypoxia conditions comparing to normoxia.
cancer cell lines. These tracks included transcription factor
CHIP-seq clusters from the ENCODE project [Encyclopedia
of DNA Elements, (35)], CpG island information, DNAase
hypersensitivity information (also from ENCODE) and TFBS
(Transcription Factor Binding Site) conservation information
across human mouse and rat. This showed that both of
these transcription factors have regulatory target sites in the
promoter regions of both MGAT5 and ST3GAL4 confirmed
by CHIP-seq, in likely promoter regions confirmed by DNAase
hypersensitivity, the presence of a CpG island, and cross-
species conservation. An siRNA targeted inhibitory approach was
undertaken to confirm this. GATA2 expression was assessed by
Western blotting and qRT-PCR in the ovarian cancer isogenic
cell line pair, A2780 and A2780cis, and GATA3 expression in
the isogenic PEO1 and PEO4 pair of cell lines, cultured in
0.5% hypoxia. This 0.5% percentage of hypoxia was chosen
as culturing in this exposure showed the most significant
alterations in glycosylation and migration. Results show that
the expression levels of GATA TFs and the glycosyltransferases
were decreased after 24 h hypoxia (0.5%) and increased after
48 h hypoxia (0.5%) exposure in all cell lines at the protein
expression levels and mostly at the mRNA expression level
(Figure 6). When GATA TFs mRNA expression levels were
knocked down using siRNA, the GATAs and glycosyltransferase
levels were mostly significantly decreased at 48 h hypoxia (0.5%)
exposure, but not at 24 h 0.5% exposure (Figure 6, Figure S5,
Table S4). This observation, while present at the protein level
(Figure 6B) was more pronounced at the gene expression level
(Figure 6A, Table S4).
DISCUSSION
From the literature, we know that epigenetics, glycosylation and
hypoxia, play key roles in cancer progression, cancer cell survival
and treatment response (36). However, little is known as to how
all three may potentially be integrated in this process.
DNA Methylation Alters in Hypoxia in a
Time-Dependent Manner, and May Be
Related to the Oxygen Dependant Enzyme
TET
Firstly, the impact that hypoxia exposure (0.5–2%O2) might have
in altering DNA methylation was assessed. Results demonstrated
that following differential exposure to hypoxia for 24 and 48 h,
significant changes in global DNA methylation were observed
in all six cell lines, in comparison to cells cultured in normoxic
(21% O2) conditions. Specifically, DNA methylation increased
significantly after 24 h, but decreased significantly after 48 h (p
≤ 0.05). This was observed predominantly for the 0.5 and 1% O2
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FIGURE 5 | Changes seen in UPLC N-glycan profiles, are associated with the mRNA expression levels of glycosyltransferases. Quantitative RT-PCR gene expression
analyses were undertaken for selected glycosyltransferases (MGAT5 and ST3GAL4) and enzymes involved in the sugar nucleotide donor pathway (MPI, TSTA3, and
GMDS) following the culturing of cells in differential hypoxic conditions (0.5–2% O2) compared to normoxia (21% O2) controls. The relative expression level of each
gene was calculated according to the ddCt normalized with TATA-Box Binding Protein (TBP). Each condition was undertaken on one biological replicate (n = 1) and
three technical replicates (n = 3).
exposure. Observed changes in DNA methylation following 2%
O2 exposure were small and not significant (Figure 1). While the
paradigm of hypoxia inducing global DNA demethylation with
site specific hypermethylation, is a widely accepted finding (37),
the shift from increased to decreased DNA methylation between
the 24 and 48 h hypoxic exposure times has not been observed
previously. This may possibly be explained by the action of the
oxygen dependant enzyme Ten Eleven Translocation (TET). TET
demethylates DNA through the oxidation of 5-methylcytosine
(5-meC), in a site-specificmanner and has previously been shown
to have reduced activity after 24 h of 0.5% hypoxia exposure (37).
Increases in Larger More Branched and
Sialylated Glycans on Secreted
Glycoproteins From Cancer Cells in
Hypoxia Aids to Their Metastatic
Capabilities
In relation to the N-glycan profiles, significant changes in
glycosylation were observed in 0.5–2% hypoxia, namely a
decrease in core fucosylated and high mannosylated glycans,
and an increase in outer arm fucosylation, polylactoseamine
extensions and sialylation in all cell lines. The only exception was
for the ovarian cancer cell line PEO1 (Figure 2). The observation
for the PEO1 cells may reflect the fact that they have a longer
doubling time than the other cell lines used (38, 39), which
could impact on N-glycan signatures. This increase in the larger
triantennary sialylated structures has been previously been linked
with the formation of selectin binding structures, promoting
extravasation of circulating tumor cells, invasion and adhesion to
lymph nodes, thereby supporting metastasis (40). Interestingly,
we found substantial levels of ketodeoxynonulosonic acid (KDN)
in all our cell lines (Table S2). KDN has been found in various
cancer tissues including ovarian cancer, and the ratio of KDN
levels to other sialic acid types (Neu5Ac and Neu5Gc), has
been found to be predictive of the metastatic potential of cells.
Importantly, hypoxia regulates the expression of KDNprocessing
enzymes, resulting in increased update of KDN precursors from
the environment (41). Interestingly, this form of sialic acid
is normally found in lower vertebrates and on the cell wall
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FIGURE 6 | Hypoxia alters mRNA expression of MGAT5 and ST3GAL4 through the regulation of GATA2 and 3. Expression of the GATA transcription factors (GATA2
and 3) and the glycosyltransferases MGAT5, ST3GAL4, in normoxia (21% O2) and 0.5% hypoxia conditions, before and after siGATA knockdown at (A) the gene
expression level, measured by quantitative RT-PCR analysis. Each sample represents of 2 biological replicates (n = 2). The relative expression level of each gene was
calculated according to the ddCt normalized with TBP; and at (B) the protein level as determined by densitometry (Image J)(Western blots are in Figure S5). Each
condition was carried out on 3 biological replicates (n = 3). Significant changes for only siRNA comparisons are starred: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 (T-test)
and all P-values for this figure including comparisons of 24 and 48 h hypoxia exposure with normoxia are in Table S4.
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polysaccharides of pathogenic bacteria (42). This observation
may indicate the presence of these bacteria in cancer cells and
cancer tissues (43–45). In the present study, there were no
significant changes in KDN (GP29) in hypoxia conditions, with
the exception of the PEO4 cells where increased expression of
KDN was observed at 24 h in 1% hypoxia (Figure 2).
Increases in EMT and Migration of Cancer
Cells in Hypoxia Increases Their
Aggressiveness and Invasive Potential
The metastatic capability of all 6 cell lines was assessed using
a combination of the migration assay (Oris cell assay) and
determining the relative expression of proteins known to be
involved in cell adhesion and cell motility. All cell lines
grown in 0.5% hypoxia demonstrated a significant increase in
migration compared to cells grown in normoxia (21% O2)
(Figure 3). This increased migration was maintained in 1%
hypoxia and 2% hypoxia for the A2780 and MDA-MB-231 cell
lines, respectively. Glycosylation, EMT and migration of PEO1
and MDA-MB-436 in a hypoxic environment, was the least
affected when compared to the other cell lines (Figures 2, 3).
In general, longer hypoxia exposure (48 h) and lower O2
percentages (0.5% O2) was associated with more significant
increases in EMT (expression of E-cadherin, vimentin and
N-cadherin) and cell migration in all cell lines. It is well-
documented that hypoxia induces migration and increases tumor
cell aggressiveness reflecting the many pathways that are HIF-
regulated. The main contributor in the literature appears to be
HIF1-α (46), which has shown to be increased in all hypoxia
exposed cell lines (Figure 4). Another mechanism which is
involved in hypoxia induced migration is the unfolded protein
response (UPR) mechanism (47). The UPR occurs in the
endoplasmic reticulum (ER), when misfolded proteins build
up due to high metabolic rates, limited supplies of glucose,
and extreme decreases in O2 availability (48). The ER is also
the start site of protein glycosylation. Hypoxia induced UPR
is also implicated in the induction of EMT in many cancers,
including breast and ovarian (49–51). The changes observed in
EMT, migration and glycosylation of cell secreted glycoproteins
following hypoxic exposure, particularly at the 0.5 and 1% O2
levels may enhance the invasive potential of these cells in highly
hypoxic tumors such as ovarian and Triple Negative Breast
Cancers (TNBC).
Senescence and Autophagy Alterations in
Hypoxia Promote the Cell Proliferation and
Metastasis, Apoptosis Increases Only in
Chemosensitive Cell Lines
Alterations in markers which are well-established with other
cellular events such as apoptosis and senescence were examined.
Interestingly, PARP cleavage, indicative of cellular apoptosis,
showed an increase in chemosensitive cells (A2780 and PEO1),
but a decrease in chemoresistant cell lines (A2780cis, PEO4 and
MDA-MB-436) (Figure 4). LC3 autophagy marker was increased
in all cells lines in hypoxia conditions, although significantly only
in A2780cis, PEO1, and PEO4, and this marker was not expressed
in MDA-MB-231 in the given conditions (Figure 4). Tumor
cells use autophagy to support self-proliferation and metastasis;
leading to poor disease prognosis (52), which indicates that
hypoxia aids to these tumor features. It is of note that while p21
was decreased in the PEO4 cell line with increasing hypoxia, there
was a significant increase in the protein levels of LC3 possibly
reflecting the innate chemoresistance of this cell line and the need
to maintain viability.
Hypoxia May Impact GATAs Expression
Through Regulation of DNA Methylation
Levels and GATAs Then Increase
Expression of Highly Branched and
Sialylated Glycans Through Increases in
Particular Glycosyltransferases
To shed more light on the origin of glycan alterations as well as
the changes in cell migration and EMT in hypoxia, especially at
the lower oxygen levels (0.5%), the expression of the glycosylation
enzymes, previously found dysregulated in the ovarian cancer cell
line OVCAR3 under demethylation conditions, was investigated
(53) (Figure 5). This list of enzymes included enzymes involved
in branching and sialylation of N-linked glycans, specifically
MGAT5 and ST3GAL4. Potential TFs, GATA1-3 for these
glycosyltransferase enzymes, had previously been identified in
silico. An siRNA targeted inhibitory approach was undertaken
to see how the expression of these glycosyltransferases was
affected. Results demonstrated that the protein expression
levels of the GATAs and the glycosyltransferase levels were
decreased at 48 h 0.5% hypoxia exposure, but not at 24 h
(Figure 6, Figure S5).
These increases or decreases were significant mostly at the
mRNA levels, some results were also evident at the protein
level (p ≤ 0.05) (Figure 6, Table S4). Interestingly, there was
a decrease in the expression levels of both GATA2 and 3
and MGAT5 and ST3GAL4 glycosyltransferases after 24 h of
hypoxia exposure with increased expression after 48 h, both at
the mRNA and protein level (Figure 6). This was in contrast to
the DNA methylation levels (Figure 1), where DNA methylation
was increased after 24 h of hypoxia exposure and decreased
after 48 h (Figure 1). GATA3 interacts and stabilizes the HIF
protein and increases tumor cell migration and invasiveness
under hypoxic conditions (10). GATA2 has not as yet been linked
with hypoxia. However, it is known that DNA methylation is
important for GATA2 transcriptional regulation (54). Therefore,
we hypothesize that hypoxia impacts on the expression of
GATAs, through regulation of global DNA methylation levels.
Increased expression of GATA TFs then increases the expression
of MGAT5 and ST3GAL4 glycosyltransferases, leading to
increases in levels of highly branched and sialylated glycans
and their expression aids to increase/enhance the migration of
the ovarian and breast cancer cell lines in hypoxic conditions.
Further studies are warranted to test that hypothesis to focus
on the proposed GATA2/3 and ST3GAL4/MGAT5 mechanism,
in relation to the specific alterations observed in secreted
N-linked glycomes.
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CONCLUSION
Global hypermethylation was observed at 24 h and global
hypomethylation at 48 h in all cell lines exposed to 0.5–
2% hypoxia. Concomitantly, glycosylation on secreted cell
glycoproteins changed to highly branched and sialylated glycan
structures. These same structures are known to be involved in
increased aggressiveness and increased metastatic capabilities
(41). In hypoxia, these ovarian and breast cancer cells also
demonstrated increased expression of EMT markers and an
increased migratory potential. It is well-documented that DNA
methylation is an important regulator of the GATA2 and GATA3
transcription factors (TFs). When GATA TFs levels decreased
after siRNA knockdown, the levels of MGAT5 and ST3GAL4,
directly involved in N-glycan branching and sialylation, were
also decreased at 48 h hypoxia (0.5%) exposure. Potentially,
hypoxia may act as a driver of GATA regulation through its
altered DNA methylation. While it has be shown that GATA3
is required for the stabilization of a hypoxic microenvironment
through binding with HIF1-α, this current study shows the
possible role of GATA 2 and GATA3 in altering the glycosylation
of tumor glycoproteins, thereby potentially contributing to cell
invasiveness. In a recent study, a GATA3-specific DNAzyme
(hgd40) was used to inhibit GATA3, which resulted in
successfully protecting mice from chronic inflammation caused
by ulcerative colitis (55). A similar study has yet to be performed
in cancer. In summary, this is the first in vitro study to investigate
DNA methylation, hypoxia and N-glycan profiling together in
the in vitro setting, and highlights the complexity of these key
integrated tumor microenvironmental features.
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Figure S1 | GATA3 concentration optimisation.
Figure S2 | Western blot images of the EMT markers, E-cadherin, N-cadherin and
Vimentin, in hypoxia treated cells (n = 3, shown are representative blots). Images
show normoxia (21% O2), 0.5, 1, and 2% after 24 and 48 h exposure.
Figure S3 | Histogram profiles representing the percentage phases of the cell
cycle, G1, S, G2, before and in hypoxia. All experiments represent three biological
experiments are n = 3.
Figure S4 | Hypoxia alters senescence, apoptosis and autophagy specifically.
Representative Western blots of the (i) senescence associated proteins (p16, Rb,
p21, (ii) autophagy associated LC3 and (iii) the apoptosis marker PARP of 4
ovarian cancer cell lines and 2 TNBC cell lines in differential hypoxia compared to
normoxia control cultures (21% O2 ). Hypoxia induction is confirmed by
appreciation of the hypoxia marker HIF1α. All results represent three biological
experiments (n = 3).
Figure S5 | SiGATA2/3 knockdown alters the levels of MGAT5 and ST3GAL4.
Western blot analysis of siGATA2/3 knockdown in 4 ovarian cancer cell lines.
GATA2 was knocked down in A2780 and A2780cis and GATA3 was knocked
down in PEO1 and PEO4 in hypoxia exposed cells compared to controls. All
results represent three biological experiments (n = 3).
Table S1 | List of all glycans from all 6 cell lines and how they were pooled
into features.
Table S2 | Detailed assignments of N-glycans from secreted glycoproteins of all
6 cell lines using UPLC and exoglycosidase digestions.
Table S3 | Mass spectrometry data in negative mode of secreted N-glycome from
cell glycoproteins.
Table S4 | P-values for siGATA knock down experiments (Figure 6).
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